# Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms

> **NCT01194440** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 63 (actual)

## Conditions studied

- Ductal Carcinoma in Situ
- Estrogen Receptor-positive Breast Cancer
- Progesterone Receptor-positive Breast Cancer
- Stage I Breast Cancer
- Stage II Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer

## Interventions

- **DRUG:** letrozole
- **DRUG:** zoledronic acid

## Key facts

- **NCT ID:** NCT01194440
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2018-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01194440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01194440, "Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01194440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*